Minerva Neurosciences (NERV) Total Current Liabilities (2013 - 2026)

Minerva Neurosciences has reported Total Current Liabilities for 14 years, with the latest figure at $4.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 130.19% year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $4.5 million (up 130.19% YoY), and the FY2025 full-year result was $2.3 million, down 19.26% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $4.5 million, up from $2.3 million in the prior quarter.
• The five-year high for Total Current Liabilities was $4.5 million in Q3 2024, with the low at $1.4 million in Q4 2022.
• Historically, Total Current Liabilities has averaged $2.9 million across 5 years, with a median of $2.8 million in 2024.
• Annual changes were most pronounced in 2022 — Total Current Liabilities tumbled 51.13% — and 2023, when it surged 142.49%.
• Minerva Neurosciences' Total Current Liabilities stood at $1.4 million in 2022, then soared by 142.49% to $3.3 million in 2023, then decreased by 15.08% to $2.8 million in 2024, then slipped by 19.26% to $2.3 million in 2025, then soared by 95.69% to $4.5 million in 2026.
• The last three Total Current Liabilities figures came in at $4.5 million (Q1 2026), $2.3 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.